Ganciclovir vs Valganciclovir — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor

Ganciclovir

Brand: Ganciclovir

First FDA approval: 2010-04-30

Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor

Valganciclovir

Brand: VALGANCICLOVIR

First FDA approval: 2001-03-29

Lowest NADACAcquisition cost floor across all NDCs

$91.38Per unit

$1.44Per unit

Average NADACAcross all dosage forms and strengths

$91.38Up to $91.38

$1.73Up to $1.94

Generic manufacturersActive ANDA holders — FDA Orange Book

55 total ANDAs filed

1115 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$13.6MFull year

$41.9MFull year

Part D claims (CY24)Total fills, all strengths

28K17K beneficiaries

169K56K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$491Per claim, all NDCs

$248Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

3Limited friction

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes5 manufacturers

Yes11 manufacturers